Gene therapy company, uniQure $QURE has transitioned from a bearish to a bullish market. Let's take a look at the daily chart.QURE Daily Chart(click to enlarge)Rollercoaster:- The daily chart shows a rollercoaster ride during 2014 and 2015.- After surging from below 10 in 2014 to 36, price dipped sharply in the second half of 2015 into 2016.Rounded Bottom:- Then price started to stall when it fell below 10.00.- Still there was a bearish bias until July 2017. Then, we started to see the QURE round out a price bottom.The Pop:- The price action in July and into October suggested anticipation of recovery. - This week's bullish surge confirmed that sense of recovery. Consolidation Ahead:- I think the market has shifted to a bullish mode, but we should note that the bullish push actually started since July. - Therefore, it might need to cool off before going any higher. - At this point, we should treat the 11-12 area as key support if price does pullback to this area. - I think ultimately, after some consolidation, there is upside towards the 22 area, an area involving common support/resistance pivots. Here's an excerpt from Zacks.com regarding the earnings report before QURE's surge:On Thursday, shares of leading gene therapy company uniQure QURE are skyrocketing, up over 50% in morning trading after it announced that it will launch a pivotal study next year testing AMT-061, the company’s promising gene therapy candidate to treat patients with hemophilia B. AMT-061 has been advanced after several meetings with the FDA and the European Medicines Agency (EMA). The therapy combines an AAV5 vector with the factor IX (FIX)-Padua gene variant, which contains a protein with a single amino acid substitution and has shown an eight-nine-fold increase in FIX activity compared to wild-type FIX protein in preclinical testing. AMT-061 is also structurally identical to uniQure’s therapy AMT-060, which has already been tested in 10 patients but contains two nucleotide substitutions in the coding sequence for FIX "Our mission in hemophilia B has always been to develop the safest and most effective gene therapy with the broadest application to patients. We believe AMT-061 moves us closer to this goal, as it has the potential to provide optimized clinical and tolerability benefits to nearly all severe and moderately severe patients with hemophilia B," stated Matthew Kapusta, chief executive officer of uniQure. Hemophilia B, also known as FIX deficiency or Christmas disease, is a genetic disorder that is caused by missing or defective factor IX, a clotting protein; it is passed down from parents to children, but roughly one-third of cases are caused by a spontaneous mutation. According to the CDC, hemophilia occurs in approximately 1 in 5,000 live births, while about 20,000 people live with the disorder in the U.S. The FDA agreed that AMT-061 should be included under the existing Breakthrough Therapy designation and Investigational New Drug (IND), while the EMA agreed to label the therapy under PRIME. The trial will be open-label and evaluate a single dose of AMT-061, and the primary endpoint will be the prevention of bleedings. UniQure said that patients will serve as their own control, with baselines to be established during a six-month observational lead-in phase.